L3VLUP
ProSign in

IMVT · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

IMVTGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • IMVT
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterIMVTGILD
Q3 20203 holders, $60m25 holders, $14.2bn
Q4 20203 holders, $34m27 holders, $13.4bn
Q1 20213 holders, $22m24 holders, $14.5bn
Q2 20212 holders, $41m18 holders, $14.9bn
Q3 20211 holders, $2.1m20 holders, $16.4bn
Q4 20211 holders, $930k20 holders, $16.8bn
Q1 20221 holders, $745k28 holders, $13.2bn
Q2 2022none listed holders, n.a.26 holders, $13.6bn
Q3 20222 holders, $21m24 holders, $13.3bn
Q4 20222 holders, $24m32 holders, $21.1bn
Q1 20233 holders, $30m27 holders, $21.8bn
Q2 20233 holders, $49m24 holders, $20.7bn
Q3 20235 holders, $111m24 holders, $20.0bn
Q4 20235 holders, $205m22 holders, $21.5bn
Q1 20244 holders, $176m30 holders, $20.3bn
Q2 20245 holders, $136m28 holders, $18.5bn
Q3 20244 holders, $135m29 holders, $24.2bn
Q4 20243 holders, $51m28 holders, $25.9bn
Q1 20253 holders, $45m33 holders, $32.0bn
Q2 20254 holders, $81m27 holders, $30.9bn
Q3 20253 holders, $80m23 holders, $29.4bn
Q4 20253 holders, $101m25 holders, $34.3bn
Q1 20263 holders, $90m25 holders, $38.5bn
Q2 20264 holders, $927m26 holders, $34.2bn
IMVT

Immunovant Inc

Holders
4
Reported value
$81m
Buyers
3
Sellers
1

Breadth +2 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
27
Reported value
$30.9bn
Buyers
18
Sellers
10

Breadth +8 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q2 2025

Among the 30 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only IMVT (3)

ExodusPoint Capital Management LP, Farallon Capital Management LLC, Point72 Asset Management LP

Only GILD (26)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Holocene Advisors LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Wellington Management Group LLP, and 1 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →